A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain.

ABSTRACT:

Background

Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose-limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin, to investigate if they could be used in combination to provide superior analgesia.

Methods

Using electrophysiological single-unit recordings taken from spinal wide dynamic range neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injectio

SUBMITTER: Lockwood SM 

PROVIDER: S-EPMC6618140 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature